Skip Navigation
Skip to contents

Intest Res : Intestinal Research

IMPACT FACTOR

Previous issues

Page Path
HOME > Browse articles > Previous issues
16 Previous issues
Filter
Filter
Article category
Keywords
Authors
Volume 17(2); April 2019
Prev issue Next issue
Editorial
IBD
Can vitamin D supplementation help control inflammation in inflammatory bowel disease beyond its classical role in bone health?
Sung Wook Hwang
Intest Res 2019;17(2):157-159.   Published online April 24, 2019
DOI: https://doi.org/10.5217/ir.2019.00038
PDFPubReaderePub

Citations

Citations to this article as recorded by  
  • High Risk of Fractures Within 7 Years of Diagnosis in Asian Patients With Inflammatory Bowel Diseases
    Hyung Jin Ahn, Ye-Jee Kim, Ho-Su Lee, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Beom-Jun Kim, Sang Hyoung Park
    Clinical Gastroenterology and Hepatology.2022; 20(5): e1022.     CrossRef
  • Jianpi Qingchang Bushen decoction improves inflammatory response and metabolic bone disorder in inflammatory bowel disease-induced bone loss
    Ya-Li Zhang, Qian Chen, Lie Zheng, Zi-Wei Zhang, Yu-Jun Chen, Yan-Cheng Dai, Zhi-Peng Tang
    World Journal of Gastroenterology.2022; 28(13): 1315.     CrossRef
  • IS DAIRY FOODS RESTRICTION MANDATORY FOR INFLAMMATORY BOWEL DISEASE PATIENTS: A MULTINATIONAL CROSS-SECTIONAL STUDY
    Pezhman ALAVINEJAD, Morteza NAYEBI, Abazar PARSI, Farnaz FARSI, Fatemeh MAGHOOL, Zeinab ALIPOUR, Mehdi ALIMADADI, Mohammed Hussien AHMED, Bahman CHERAGHIAN, Dao Viet HANG, Shabnam SHAHROKH, Mohammad Hasan EMAMI, Seyed Jalal HASHEMI, Mohamed ALBORAIE, Damo
    Arquivos de Gastroenterologia.2022; 59(3): 358.     CrossRef
  • Influence of Severe Vitamin D Deficiency on the Clinical Course of Inflammatory Bowel Disease
    Nam Seok Ham, Sung Wook Hwang, Eun Hye Oh, Jeongseok Kim, Ho-Su Lee, Sang Hyoung Park, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang
    Digestive Diseases and Sciences.2021; 66(2): 587.     CrossRef
  • Influence of Severe Vitamin D Deficiency on the Clinical Course of Inflammatory Bowel Disease
    Cong Dai, Min Jiang
    Digestive Diseases and Sciences.2021; 66(3): 919.     CrossRef
  • The effect of vitamin d-calcium co-supplementation on inflammatory biomarkers: A systematic review and meta-analysis of randomized controlled trials
    Omid Asbaghi, Mehdi Sadeghian, Hassan Mozaffari-Khosravi, Vahid Maleki, Azad Shokri, Fatemeh Hajizadeh-Sharafabad, Mohammad Alizadeh, Omid Sadeghi
    Cytokine.2020; 129: 155050.     CrossRef
  • 5,639 View
  • 140 Download
  • 5 Web of Science
  • 6 Crossref
Close layer
Reviews
IBD
Does fecal calprotectin equally and accurately measure disease activity in small bowel and large bowel Crohn’s disease?: a systematic review
Ebby George Simon, Richard Wardle, Aye Aye Thi, Jeanette Eldridge, Sunil Samuel, Gordon William Moran
Intest Res 2019;17(2):160-170.   Published online February 7, 2019
DOI: https://doi.org/10.5217/ir.2018.00114
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Fecal calprotectin (FC) is a highly sensitive disease activity biomarker in inflammatory bowel disease. However, there are conflicting reports on whether the diagnostic accuracy in Crohn’s disease is influenced by disease location. The aim of this study was to undertake a systematic review of the published literature. Relevant databases were searched from inception to November 8, 2016 for cohort and case control studies which had data on FC in patients with isolated small bowel (SB) and large bowel (LB) Crohn’s disease. Reference standards for disease activity were endoscopy, magnetic resonance imaging, computed tomography or a combination of these. The QUADAS-2 research tool was used to assess the risk of bias. There were 5,619 records identified at initial search. The 2,098 duplicates were removed and 3,521 records screened. Sixty-one full text articles were assessed for eligibility and 16 studies were included in the final review with sensitivities and specificities per disease location available from 8 studies. Sensitivities of FC at SB and LB locations ranged from 42.9% to 100% and 66.7% to 100% respectively while corresponding specificities were 50% to 100% and 28.6% to 100% respectively. The sensitivities and specificities of FC to accurately measure disease activity in Crohn’s disease at different disease locations are diverse and no firm conclusion can be made. Better studies need to be undertaken to categorically answer the effect of disease location on the diagnostic accuracy of FC.

Citations

Citations to this article as recorded by  
  • Serum food specific IgG antibodies are associated with small bowel inflammation in patients with Crohn’s disease
    Jintong Chen, Huaning Chen, Yanni Huang, Hongchai Xie, Silin Li, Chengdang Wang
    European Journal of Clinical Nutrition.2024; 78(1): 48.     CrossRef
  • Combination of leucine-rich alpha-2 glycoprotein and fecal markers detect Crohn’s disease activity confirmed by balloon-assisted enteroscopy
    Ami Kawamoto, Kento Takenaka, Shuji Hibiya, Yoshio Kitazume, Hiromichi Shimizu, Toshimitsu Fujii, Eiko Saito, Kazuo Ohtsuka, Ryuichi Okamoto
    Intestinal Research.2024; 22(1): 65.     CrossRef
  • Which biomarkers best reflect the degree of inflammation in Crohn’s disease?
    Jihye Park
    Intestinal Research.2024; 22(1): 1.     CrossRef
  • RNA Expression of MMP12 Is Strongly Associated with Inflammatory Bowel Disease and Is Regulated by Metabolic Pathways in RAW 264.7 Macrophages
    Laura Arosa, Miguel Camba-Gómez, Luis Francisco Lorenzo-Martín, Laura Clavaín, Miguel López, Javier Conde-Aranda
    International Journal of Molecular Sciences.2024; 25(6): 3167.     CrossRef
  • Circulatory resistin levels in inflammatory bowel disease: a systematic review and meta-analysis
    Amir Hossein Behnoush, Seyede Parmis Maroufi, Tara Reshadmanesh, Yasmin Mohtasham Kia, Mitra Norouzi, Seyedeh Mina Mohammadi, Aleksandra Klisic, Amirmohammad Khalaji
    BMC Gastroenterology.2024;[Epub]     CrossRef
  • Application of clinical decision support tools for predicting outcomes with vedolizumab therapy in patients with inflammatory bowel disease: A KASID multicentre study
    Kyuwon Kim, Jae Jun Park, Hyuk Yoon, Jun Lee, Kyeong Ok Kim, Eun Sun Kim, Su Young Kim, Sun‐Jin Boo, Yunho Jung, Jun Hwan Yoo, Sung Wook Hwang, Sang Hyoung Park, Suk‐Kyun Yang, Byong Duk Ye
    Alimentary Pharmacology & Therapeutics.2024; 59(12): 1539.     CrossRef
  • Fecal Calprotectin in Patients with Crohn’s Disease: A Study Based on the History of Bowel Resection and Location of Disease
    Jeongkuk Seo, Subin Song, Seung Hwan Shin, Suhyun Park, Seung Wook Hong, Sang Hyoung Park, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Sung Wook Hwang
    Diagnostics.2024; 14(8): 854.     CrossRef
  • Utility of the Endoscopic Healing Index in Identifying Active Inflammation in Patients with Crohn’s Disease: Real World Data from a Tertiary Center
    Nathaniel A. Cohen, Tenzin Choden, Emma C. Dyer, Nicole M. Garcia, Natalie K. Choi, David T. Rubin
    Digestive Diseases and Sciences.2024; 69(8): 2955.     CrossRef
  • Diagnostic Value of Quantitative Contrast‐Enhanced Ultrasound in Comparison to Endoscopy in Children With Crohn's Disease
    Slavojka Ponorac, Raja Dahmane Gošnak, Darja Urlep, Damjana Ključevšek
    Journal of Ultrasound in Medicine.2023; 42(1): 193.     CrossRef
  • Resistin, Elastase, and Lactoferrin as Potential Plasma Biomarkers of Pediatric Inflammatory Bowel Disease Based on Comprehensive Proteomic Screens
    Anto Sam Crosslee Louis Sam Titus, Kamala Vanarsa, Sanam Soomro, Anjali Patel, Jarod Prince, Subra Kugathasan, Chandra Mohan
    Molecular & Cellular Proteomics.2023; 22(2): 100487.     CrossRef
  • Fecal immunochemical test for haemoglobin versus fecal calprotectin to monitoring endoscopic activity in inflammatory bowel disease
    Patricia Latorre Añó, Jorge Torrente Sánchez, Amparo Almudena Pérez Ibañez, Jose María Tenias Burillo, Nadia Paloma Moreno Sánchez, Antonio López-Serrano, Eduardo Moreno Osset, Julián Murado Pardo, José María Paredes
    Revista Española de Enfermedades Digestivas.2023;[Epub]     CrossRef
  • Clinical Value of Detecting Fecal Calprotectin by Using Colloidal Gold Assay in Screening or Diagnosing Crohn’s Disease
    Wangdong Zhang, Yanyun Fan, Meijun Chen, Tatsuya Toyokawa
    Gastroenterology Research and Practice.2023; 2023: 1.     CrossRef
  • AGA Clinical Practice Guideline on the Role of Biomarkers for the Management of Crohn’s Disease
    Ashwin N. Ananthakrishnan, Jeremy Adler, Karen A. Chachu, Nghia H. Nguyen, Shazia M. Siddique, Jennifer M. Weiss, Shahnaz Sultan, Fernando S. Velayos, Benjamin L. Cohen, Siddharth Singh
    Gastroenterology.2023; 165(6): 1367.     CrossRef
  • Amplification of an Electrochemiluminescence-Emissive Aptamer into DNA Nanotags for Sensitive Fecal Calprotectin Determination
    Fujin Lv, Jialiang Chen, Ying Wan, Jingyi Si, Meiyan Song, Fulin Zhu, Songyuan Du, Yuzhe Shang, Tiantian Man, Longyi Zhu, Kewei Ren, Yuhao Piao, Changfeng Zhu, Sheng-Yuan Deng
    Analytical Chemistry.2023; 95(50): 18564.     CrossRef
  • Association between Fecal Calprotectin and Mucosal Healing in Pediatric Patients with Crohn’s Disease Who Have Achieved Sustained Clinical Remission with Anti-Tumor Necrosis Factor Agents
    Yoo Min Lee, Sujin Choi, Byung-Ho Choe, Hyo-Jeong Jang, Seung Kim, Hong Koh, Eun Sil Kim, Mi Jin Kim, Yon Ho Choe, Ben Kang
    Gut and Liver.2022; 16(1): 62.     CrossRef
  • Efficacy of sigmoidoscopy for evaluating disease activity in patients with ulcerative colitis
    Su Bum Park, Seong-Jung Kim, Jun Lee, Yoo Jin Lee, Dong Hoon Baek, Geom Seog Seo, Eun Soo Kim, Sang-Wook Kim, So Yeong Kim
    BMC Gastroenterology.2022;[Epub]     CrossRef
  • Fungi
    Jane Alookaran, Yuying Liu, Thomas A. Auchtung, Amirali Tahanan, Manouchehr Hessabi, Parisa Asgarisabet, Mohammad H. Rahbar, Nicole Y. Fatheree, Deborah A. Pearson, Rosleen Mansour, Melissa R. Van Arsdall, Fernando Navarro, J. Marc Rhoads
    Journal of Pediatric Gastroenterology and Nutrition.2022; 74(3): 377.     CrossRef
  • Fecal S100A12 is associated with future hospitalization and step-up of medical treatment in patients with Crohn’s disease in clinical remission: a pilot study
    Sun-Ho Lee, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Byong Duk Ye
    Intestinal Research.2022; 20(2): 203.     CrossRef
  • Ultrasonographic scores for ileal Crohn’s disease assessment: Better, worse or the same as contrast-enhanced ultrasound?
    M. Freitas, F. Dias de Castro, V. Macedo Silva, C. Arieira, T. Cúrdia Gonçalves, S. Leite, M. J. Moreira, J. Cotter
    BMC Gastroenterology.2022;[Epub]     CrossRef
  • Intestinal fatty acid binding protein is a disease biomarker in paediatric coeliac disease and Crohn’s disease
    Michael Logan, Mary MacKinder, Clare Martha Clark, Aikaterini Kountouri, Mwansa Jere, Umer Zeeshan Ijaz, Richard Hansen, Paraic McGrogan, Richard K. Russell, Konstantinos Gerasimidis
    BMC Gastroenterology.2022;[Epub]     CrossRef
  • Usefulness of ultrasonography for small intestinal evaluations in pediatric Crohn's disease
    Takeru Okuhira, Atsushi Yoden, Emiri Kaji, Masano Otani‐Akamatsu, Keisuke Inoue, Tomoki Aomatsu, Kimitaka Takitani, Akira Ashida
    Pediatrics International.2022;[Epub]     CrossRef
  • Intestinal ultrasonography and fecal calprotectin for monitoring inflammation of ileal Crohn’s disease: two complementary tests
    José María Paredes, Tomás Ripollés, Ángela Algarra, Rafael Diaz, Nadia Moreno, Patricia Latorre, María Jesús Martínez, Pilar Llopis, Antonio López, Eduardo Moreno-Osset
    Intestinal Research.2022; 20(3): 361.     CrossRef
  • Fecal calprotectin predicts endoscopic activity and mucosal healing of small bowel Crohn’s disease evaluated by double-balloon endoscopy
    Wei Han, Juan Wu, Peipei Zhang, Naizhong Hu, Qiao Mei, Jing Hu
    International Journal of Colorectal Disease.2022; 37(9): 1953.     CrossRef
  • Fecal Calprotectin for Small Bowel Crohn’s Disease: Is It a Cutoff Issue?
    Cristina Romero-Mascarell, Gloria Fernández-Esparrach, Cristina Rodríguez-De Miguel, Maria Carme Masamunt, Sonia Rodríguez, Jordi Rimola, Miguel Urpí, Gherzon Simon Casanova, Ingrid Ordás, Elena Ricart, Berta Caballol, Agnès Fernández-Clotet, Julià Panés,
    Diagnostics.2022; 12(9): 2226.     CrossRef
  • A Practical Guide for Faecal Calprotectin Measurement: Myths and Realities
    Ferdinando D’Amico, Stéphane Nancey, Silvio Danese, Laurent Peyrin-Biroulet
    Journal of Crohn's and Colitis.2021; 15(1): 152.     CrossRef
  • The utility of faecal and urine biomarkers for small bowel diseases
    M.S. Ismail, Serhiy Semenov, Deirdre McNamara
    Current Opinion in Gastroenterology.2021; 37(3): 284.     CrossRef
  • Predicting disease course in ulcerative colitis using stool proteins identified through an aptamer-based screen
    Sanam Soomro, Suresh Venkateswaran, Kamala Vanarsa, Marwa Kharboutli, Malavika Nidhi, Ramya Susarla, Ting Zhang, Prashanth Sasidharan, Kyung Hyun Lee, Joel Rosh, James Markowitz, Claudia Pedroza, Lee A. Denson, Jeffrey Hyams, Subra Kugathasan, Chandra Moh
    Nature Communications.2021;[Epub]     CrossRef
  • Anti-Microbial Antibody Response is Associated With Future Onset of Crohn’s Disease Independent of Biomarkers of Altered Gut Barrier Function, Subclinical Inflammation, and Genetic Risk
    Sun-Ho Lee, Williams Turpin, Osvaldo Espin-Garcia, Juan Antonio Raygoza Garay, Michelle I. Smith, Haim Leibovitzh, Ashleigh Goethel, Dan Turner, David Mack, Colette Deslandres, Maria Cino, Guy Aumais, Remo Panaccione, Kevan Jacobson, Alain Bitton, A. Hill
    Gastroenterology.2021; 161(5): 1540.     CrossRef
  • Diagnostic Accuracy of Fecal Calprotectin for the Detection of Small Bowel Crohn's Disease through Capsule Endoscopy: An Updated Meta-Analysis and Systematic Review
    Eun Suk Jung, Sang Pyo Lee, Sea Hyub Kae, Jung Han Kim, Hyeong Su Kim, Hyun Joo Jang
    Gut and Liver.2021; 15(5): 732.     CrossRef
  • Optimal Cutoff Level of Fecal Calprotectin for Detecting Small Bowel Inflammation in Crohn's Disease
    Eun Soo Kim
    Gut and Liver.2021; 15(5): 637.     CrossRef
  • Diagnostic Accuracy of Non-Invasive Imaging for Detection of Colonic Inflammation in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
    Meshari T. Alshammari, Rebecca Stevenson, Buraq Abdul-Aema, Guangyong Zou, Vipul Jairath, Shellie Radford, Luca Marciani, Gordon W. Moran
    Diagnostics.2021; 11(10): 1926.     CrossRef
  • Közös felelősség a gyulladásos bélbetegség diagnosztikájában és kezelésében.
    Dóra Dohos, Adrienn Erős, Kata Szemes, Patrícia Sarlós
    Orvosi Hetilap.2021; 162(33): 1311.     CrossRef
  • Crohn's Disease Activity Quantified by Iodine Density Obtained From Dual-Energy Computed Tomography Enterography
    Bari Dane, Sean Duenas, Joseph Han, Thomas O'Donnell, Justin Ream, Shannon Chang, Alec Megibow
    Journal of Computer Assisted Tomography.2020; 44(2): 242.     CrossRef
  • Defining the Path Forward for Biomarkers to Address Unmet Needs in Inflammatory Bowel Diseases
    Gerard Honig, Caren Heller, Andrés Hurtado-Lorenzo
    Inflammatory Bowel Diseases.2020; 26(10): 1451.     CrossRef
  • Multiomic features associated with mucosal healing and inflammation in paediatric Crohn’s disease
    Henry Taylor, Jose Ivan Serrano‐Contreras, Julie A. K. McDonald, Jenny Epstein, JM Fell, Rocio C. Seoane, Jia V. Li, Julian R. Marchesi, Ailsa L. Hart
    Alimentary Pharmacology & Therapeutics.2020; 52(9): 1491.     CrossRef
  • Nested case-control study on risk factors for opportunistic infections in patients with inflammatory bowel disease
    Shan-Shan Gong, Yi-Hong Fan, Qing-Qing Han, Bin Lv, Yi Xu
    World Journal of Gastroenterology.2019; 25(18): 2240.     CrossRef
  • Clinical value of fecal calprotectin
    Amanda Ricciuto, Anne M. Griffiths
    Critical Reviews in Clinical Laboratory Sciences.2019; 56(5): 307.     CrossRef
  • 13,038 View
  • 310 Download
  • 40 Web of Science
  • 37 Crossref
Close layer
IBD
An overview of the role of exclusive enteral nutrition for complicated Crohn’s disease
Mustafa Adamji, Andrew S Day
Intest Res 2019;17(2):171-176.   Published online December 3, 2018
DOI: https://doi.org/10.5217/ir.2018.00079
AbstractAbstract PDFPubReaderePub
The role and efficacy of exclusive enteral nutrition (EEN) in the treatment of luminal Crohn’s disease (CD) has been well established over the last 2 decades. Consequently, in many centers nutritional therapy is now considered first line therapy in the induction of remission of active CD. However, the use of nutritional therapy in complicated CD has yet to be fully determined. This article aimed to review case reports and clinical trials published in the last decade that have considered and evaluated nutritional therapy in the setting of complicated CD in children and adults. Published literature focusing upon the use of nutritional therapy as part of medical therapy in the management of complicated CD were identified and reviewed. Although there continue to be various interventions utilized for complicated CD, the currently available literature demonstrates that nutritional therapies, especially EEN, have important roles in the management of these complex scenarios. Further assessments, involving large numbers of patients managed with consistent approaches, are required to further substantiate these roles.

Citations

Citations to this article as recorded by  
  • Mycobacterium avium ssp. paratuberculosis and Crohn’s Disease—Diagnostic Microbiological Investigations Can Inform New Therapeutic Approaches
    John M. Aitken, Jack E. Aitken, Gaurav Agrawal
    Antibiotics.2024; 13(2): 158.     CrossRef
  • Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) (Version 4.1) – living guideline
    Andreas Sturm, Raja Atreya, Dominik Bettenworth, Bernd Bokemeyer, Axel Dignass, Robert Ehehalt, Christoph-Thomas Germer, P. C. Grunert, Ulf Helwig, Karoline Horisberger, Klaus Herrlinger, Peter Kienle, Torsten Kucharzik, Jost Langhorst, Christian Maaser,
    Zeitschrift für Gastroenterologie.2024; 62(08): 1229.     CrossRef
  • Mechanisms of Action of Exclusive Enteral Nutrition and Other Nutritional Therapies in Crohn’s Disease
    Ramasatyaveni Geesala, Pratik Gongloor, Neeraja Recharla, Xuan-Zheng Shi
    Nutrients.2024; 16(21): 3581.     CrossRef
  • Adjunct polymeric exclusive enteral nutrition helps achieve biochemical remission in active Crohn’s disease in adults irrespective of disease location and concomitant corticosteroid use
    Hellen Kuo, Katrina Tognolini, Rumbidzai Mutsekwa, Dheeraj Shukla, Laura Willmann, Hadi Moattar, Alexander Dorrington, Naveed Ishaq, Maneesha Bhullar, John Edwards, Waled Mohsen, Pradeep Kakkadasam Ramaswamy
    Frontline Gastroenterology.2024; : flgastro-2024-102749.     CrossRef
  • Is Salt at Fault? Dietary Salt Consumption and Inflammatory Bowel Disease
    Rebecca Kuang, Stephen J D O’Keefe, Claudia Ramos del Aguila de Rivers, Filippos Koutroumpakis, David G Binion
    Inflammatory Bowel Diseases.2023; 29(1): 140.     CrossRef
  • The Role of the Gut Microbiota in the Relationship Between Diet and Human Health
    Bryce K. Perler, Elliot S. Friedman, Gary D. Wu
    Annual Review of Physiology.2023; 85(1): 449.     CrossRef
  • Global research trends on diet and nutrition in Crohn’s disease
    Muna Shakhshir, Sa'ed H Zyoud
    World Journal of Gastroenterology.2023; 29(20): 3203.     CrossRef
  • Enterale Ernährungstherapien beim pädiatrischen M. Crohn Anwendungen und Wirkweise
    André Hörning, Anjona Schmidt-Choudhury
    Aktuelle Ernährungsmedizin.2023; 48(03): 183.     CrossRef
  • Identifying Microbiome Dynamics in Pediatric IBD: More than a Family Matter
    Nikolas Dovrolis, Anastasia Moschoviti, Smaragdi Fessatou, George Karamanolis, George Kolios, Maria Gazouli
    Biomedicines.2023; 11(7): 1979.     CrossRef
  • Unraveling the Impact of Gut and Oral Microbiome on Gut Health in Inflammatory Bowel Diseases
    Hala Elzayat, Ghaidaa Mesto, Farah Al-Marzooq
    Nutrients.2023; 15(15): 3377.     CrossRef
  • Interplay between inflammatory bowel disease therapeutics and the gut microbiome reveals opportunities for novel treatment approaches
    Catherine O’Reilly, Susan Mills, Mary C. Rea, Aonghus Lavelle, Subrata Ghosh, Colin Hill, R. Paul Ross
    Microbiome Research Reports.2023;[Epub]     CrossRef
  • Current understanding of the aetiology and pathogenesis of inflammatory bowel diseases (Part 2): the role of the microbiome and nutritional factors
    A. I. Khavkin, K. M. Nikolaychuk, E. V. Shrayner, D. R. Shaimardanova, A. S. Veremenko, I. D. Levchenko, P. Ya. Platonova, M. F. Novikova, V. V. Dudurich
    Experimental and Clinical Gastroenterology.2023; (12): 164.     CrossRef
  • FODMAPs, inflammatory bowel disease and gut microbiota: updated overview on the current evidence
    Catarina D. Simões, Marta Maganinho, Ana S. Sousa
    European Journal of Nutrition.2022; 61(3): 1187.     CrossRef
  • Effects of Olive Oil and Its Components on Intestinal Inflammation and Inflammatory Bowel Disease
    Josip Vrdoljak, Marko Kumric, Marino Vilovic, Dinko Martinovic, Iris Jeroncic Tomic, Mladen Krnic, Tina Ticinovic Kurir, Josko Bozic
    Nutrients.2022; 14(4): 757.     CrossRef
  • Exclusive enteral nutrition: An optimal care pathway for use in children with active luminal Crohn's disease
    Deirdre Burgess, Kathleen H McGrath, Caitlin Watson, Tanya Collins, Stephanie Brown, Katie Marks, Kate Dehlsen, Kim Herbison, Emma Landorf, Laura Benn, Julia Fox, Ming Liew
    Journal of Paediatrics and Child Health.2022; 58(4): 572.     CrossRef
  • Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – August 2021 – AWMF-Registernummer: 021-004
    Andreas Sturm, Raja Atreya, Dominik Bettenworth, Bernd Bokemeyer, Axel Dignaß, Robert Ehehalt, Christoph Germer, Philip C. Grunert, Ulf Helwig, Klaus Herrlinger, Peter Kienle, Martin E. Kreis, Torsten Kucharzik, Jost Langhorst, Christian Maaser, Johann Oc
    Zeitschrift für Gastroenterologie.2022; 60(03): 332.     CrossRef
  • The Optimal Management of Fistulizing Crohn’s Disease: Evidence beyond Randomized Clinical Trials
    Panu Wetwittayakhlang, Alex Al Khoury, Gustavo Drügg Hahn, Peter Laszlo Lakatos
    Journal of Clinical Medicine.2022; 11(11): 3045.     CrossRef
  • Laser Therapy in Perianal Fistulas
    Mircea Sandor, Maur Sebastian Horgos, Ioan Lucian Borza, Rodica Negrean, Mihai Botea, Szuhai Erika Bimbo, Anca Huniadi, Liliana Sachelarie, Loredana Liliana Hurjui, Irina Mihaela Jemnoschi Hreniuc
    Applied Sciences.2022; 12(23): 12433.     CrossRef
  • Enterale Ernährungstherapien beim pädiatrischen M. Crohn
    André Hörning, Anjona Schmidt-Choudhury
    Kinder- und Jugendmedizin.2022; 22(06): 439.     CrossRef
  • Dietary patterns, beliefs and behaviours among individuals with inflammatory bowel disease: a cross‐sectional study
    K. J. Kamp, B. Pennings, D. Javelli, G. Wyatt, B. Given
    Journal of Human Nutrition and Dietetics.2021; 34(2): 257.     CrossRef
  • Alterations in drug disposition in older adults: a focus on geriatric syndromes
    Dorsa Maher, Nagham Ailabouni, Arduino A. Mangoni, Michael D. Wiese, Emily Reeve
    Expert Opinion on Drug Metabolism & Toxicology.2021; 17(1): 41.     CrossRef
  • Nutritional Therapy Strategies in Pediatric Crohn’s Disease
    Charlotte M. Verburgt, Mohammed Ghiboub, Marc A. Benninga, Wouter J. de Jonge, Johan E. Van Limbergen
    Nutrients.2021; 13(1): 212.     CrossRef
  • Enteral nutrition modulation with n-3 PUFAs directs microbiome and lipid metabolism in mice
    Fuzheng Tao, Xi Xing, Jiannong Wu, Ronglin Jiang, Tamil Selvan Anthonymuthu
    PLOS ONE.2021; 16(3): e0248482.     CrossRef
  • Fish Sidestream-Derived Protein Hydrolysates Suppress DSS-Induced Colitis by Modulating Intestinal Inflammation in Mice
    Maria G. Daskalaki, Konstantinos Axarlis, Tone Aspevik, Michail Orfanakis, Ourania Kolliniati, Ioanna Lapi, Maria Tzardi, Eirini Dermitzaki, Maria Venihaki, Katerina Kousoulaki, Christos Tsatsanis
    Marine Drugs.2021; 19(6): 312.     CrossRef
  • Efficacy and tolerability of exclusive enteral nutrition in adult patients with complicated Crohn’s disease
    Sanchit Sharma, Arti Gupta, Saurabh Kedia, Samagra Agarwal, Namrata Singh, Sandeep Goyal, Saransh Jain, Vipin Gupta, Pabitra Sahu, Sudheer Kumar Vuyyuru, Bhaskar Kante, Raju Sharma, Rajesh Panwar, Peush Sahni, Govind Makharia, Vineet Ahuja
    Intestinal Research.2021; 19(3): 291.     CrossRef
  • Risk Factors for Disease Behavior Evolution and Efficacy of Biologics in Reducing Progression in Pediatric Patients with Nonstricturing, Nonpenetrating Crohn's Disease at Diagnosis: A Single-Center Experience in Korea
    Hyun Jin Kim, Seak Hee Oh, Sung Hee Lee, Yu-Bin Kim, Dae Yeon Kim, Sang Hyoung Park, Byong Duk Ye, Suk-Kyun Yang, Kyung Mo Kim
    Gut and Liver.2021; 15(6): 851.     CrossRef
  • The Effect of Formula-based Nutritional Treatment on Colitis in a Murine Model
    Sooyoung Jang, Younjuong Kim, Changjun Lee, Bomi Kwon, Jihye Noh, Jai J. Jee, Sang Sun Yoon, Hong Koh, Sowon Park
    Journal of Korean Medical Science.2021;[Epub]     CrossRef
  • 8,382 View
  • 301 Download
  • 26 Web of Science
  • 27 Crossref
Close layer
IBD
Epithelial-microbial diplomacy: escalating border tensions drive inflammation in inflammatory bowel disease
Stephanie J King, Declan F McCole
Intest Res 2019;17(2):177-191.   Published online March 7, 2019
DOI: https://doi.org/10.5217/ir.2018.00170
AbstractAbstract PDFPubReaderePub
Inflammatory bowel diseases (IBD) are chronic conditions of the gastrointestinal tract-the main site of host-microbial interaction in the body. Development of IBD is not due to a single event but rather is a multifactorial process where a patient’s genetic background, behavioral habits, and environmental exposures contribute to disease pathogenesis. IBD patients exhibit alterations to gut bacterial populations “dysbiosis” due to the inflammatory microenvironment, however whether this alteration of the gut microbiota precedes inflammation has not been confirmed. Emerging evidence has highlighted the important role of gut microbes in developing measured immune responses and modulating other host responses such as metabolism. Much of the work on the gut microbiota has been correlative and there is an increasing need to understand the intimate relationship between host and microbe. In this review, we highlight how commensal and pathogenic bacteria interact with host intestinal epithelial cells and explore how altered microenvironments impact these connections.

Citations

Citations to this article as recorded by  
  • Space Radiation-induced Impacts on Gut Flora, Metabolites and Multisystem Diseases
    Zhujun WU, Xin ZHANG, Yudi PANG, Yulin DENG, Zhimin WANG
    Chinese Journal of Space Science.2024; 44(5): 873.     CrossRef
  • Host–pathobiont interactions in Crohn’s disease
    Roberta Caruso, Bernard C. Lo, Grace Y. Chen, Gabriel Núñez
    Nature Reviews Gastroenterology & Hepatology.2024;[Epub]     CrossRef
  • Assembling symbiotic bacterial species into live therapeutic consortia that reconstitute microbiome functions
    Rita A. Oliveira, Eric G. Pamer
    Cell Host & Microbe.2023; 31(4): 472.     CrossRef
  • Direct and Indirect Evidence of Effects of Bacteroides spp. on Obesity and Inflammation
    Liangliang Wu, Seo-Hyun Park, Hojun Kim
    International Journal of Molecular Sciences.2023; 25(1): 438.     CrossRef
  • Inflammatory bowel disease: The role of commensal microbiome in immune regulation
    Martín Ivan Wah-Suárez, Manuel Alejandro Martínez Vázquez, Francisco Javier Bosques-Padilla
    Gastroenterología y Hepatología.2022; 45(8): 626.     CrossRef
  • Novel Potassium-Competitive Acid Blocker, Tegoprazan, Protects Against Colitis by Improving Gut Barrier Function
    Mijeong Son, I Seul Park, Soochan Kim, Hyun Woo Ma, Ji Hyung Kim, Tae Il Kim, Won Ho Kim, Jaeyong Han, Seung Won Kim, Jae Hee Cheon
    Frontiers in Immunology.2022;[Epub]     CrossRef
  • Inflammatory bowel disease in Korea: epidemiology and pathophysiology
    Jung Won Lee, Chang Soo Eun
    The Korean Journal of Internal Medicine.2022; 37(5): 885.     CrossRef
  • Inflammatory bowel disease: The role of commensal microbiome in immune regulation
    Martín Ivan Wah-Suárez, Manuel Alejandro Martínez Vázquez, Francisco Javier Bosques-Padilla
    Gastroenterología y Hepatología (English Edition).2022; 45(8): 626.     CrossRef
  • Effects of hypoxia stress on the intestinal microflora of juvenile of cobia (Rachycentron canadum)
    Wei-zheng Wang, Jian-sheng Huang, Jian-dong Zhang, Zhong-liang Wang, Hong-juan Li, Eric Amenyogbe, Gang Chen
    Aquaculture.2021; 536: 736419.     CrossRef
  • Intestinal microbiota and inflammatory bowel diseases
    Chang Soo Eun
    Journal of the Korean Medical Association.2021; 64(9): 588.     CrossRef
  • Glutathione S‐transferase theta 1 protects against colitis through goblet cell differentiation via interleukin‐22
    Jae Hyeon Kim, Jae Bum Ahn, Da Hye Kim, Soochan Kim, Hyun Woo Ma, Xiumei Che, Dong Hyuk Seo, Tae Il Kim, Won Ho Kim, Jae Hee Cheon, Seung Won Kim
    The FASEB Journal.2020; 34(2): 3289.     CrossRef
  • Pathogenesis and clinical perspectives of extraintestinal manifestations in inflammatory bowel diseases
    Jung Min Kim, Jae Hee Cheon
    Intestinal Research.2020; 18(3): 249.     CrossRef
  • The impact of maternal and early life malnutrition on health: a diet-microbe perspective
    Andrew J. Forgie, Kelsea M. Drall, Stephane L. Bourque, Catherine J. Field, Anita L. Kozyrskyj, Benjamin P. Willing
    BMC Medicine.2020;[Epub]     CrossRef
  • Melatonin in the colon modulates intestinal microbiota in response to stress and sleep deprivation
    Young Sook Park, Soo Hyung Kim, Jong Won Park, Younglim Kho, Pu Rum Seok, Jae-Ho Shin, Yoon Ji Choi, Jin-Hyun Jun, Hee Chan Jung, Eun Kyung Kim
    Intestinal Research.2020; 18(3): 325.     CrossRef
  • Role of the microbiota in ileitis of a mouse model of inflammatory bowel disease—Glutathione peroxide isoenzymes 1 and 2‐double knockout mice on a C57BL background
    Fong‐Fong Chu, R. Steven Esworthy, Binghui Shen, James H. Doroshow
    MicrobiologyOpen.2020;[Epub]     CrossRef
  • Patients with Inflammatory Bowel Disease Are at an Increased Risk of Parkinson’s Disease: A South Korean Nationwide Population-Based Study
    Seona Park, Jihye Kim, Jaeyoung Chun, Kyungdo Han, Hosim Soh, Eun Ae Kang, Hyun Jung Lee, Jong Pil Im, Joo Sung Kim
    Journal of Clinical Medicine.2019; 8(8): 1191.     CrossRef
  • 9,371 View
  • 313 Download
  • 16 Web of Science
  • 16 Crossref
Close layer
Original Articles
Microbiota
Evaluation of commercial probiotic lactic cultures against biofilm formation by Cronobacter sakazakii
Anubhav Jamwal, Kavita Sharma, Rajni Chauhan, Saurabh Bansal, Gunjan Goel
Intest Res 2019;17(2):192-201.   Published online December 3, 2018
DOI: https://doi.org/10.5217/ir.2018.00106
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Background/Aims
Cronobacter sakazakii, an emergent pathogen is considered as a major concern to infants and neonates fed on reconstituted powdered infant milk formula. In conjunction with many other factors, biofilm forming capacity adds to its pathogenic potential. In view of the facts that infants are at highest risk to C. sakazakii infections, and emerging antibiotic resistance among pathogens, it is imperative to evaluate probiotic cultures for their efficacy against C. sakazakii. Therefore, pure probiotic strains were isolated from commercial probiotic products and tested for their antimicrobial and anti-biofilm activities against C. sakazakii.
Methods
A total of 6 probiotic strains were tested for their antibiotic susceptibility followed by antimicrobial activity using cell-free supernatant (CFS) against C. sakazakii. The inhibitory activity of CFS against biofilm formation by C. sakazakii was determined using standard crystal violet assay and microscopic observations.
Results
All the probiotic strains were sensitive to ampicillin, tetracycline, vancomycin and carbenicillin whereas most of the strains were resistant to erythromycin and novobiocin. Four of the 6 probiotic derived CFS possessed antimicrobial activity against C. sakazakii at a level of 40 μL. A higher biofilm inhibitory activity (>80%) was observed at initial stages of biofilm formation with weaker activity during longer incubation upto 48 hours (50%–60%).
Conclusions
The study indicated the efficacy of isolated commercial probiotics strains as potential inhibitor of biofilm formation by C. sakazakii and could be further explored for novel bioactive molecules to limit the emerging infections of C. sakazakii.

Citations

Citations to this article as recorded by  
  • Investigating the effect of Lactiplantibacillus plantarum TW57-4 in preventing biofilm formation and expression of virulence genes in Listeria monocytogenes ATCC 19115
    Arezou Rouhi, Fereshteh Falah, Marjan Azghandi, Behrooz Alizadeh Behbahani, Seyed Ali Mortazavi, Farideh Tabatabaei-Yazdi, Alireza Vasiee
    LWT.2024; 191: 115669.     CrossRef
  • Exploring Technological, Safety and Probiotic Properties of Enterococcus Strains: Impact on Rheological Parameters in Fermented Milk
    Souraya Sakoui, Reda Derdak, Oana Lelia Pop, Dan Cristian Vodnar, Fatimazahra Jouga, Bernadette-Emőke Teleky, Boutaina Addoum, Elemér Simon, Ramona Suharoschi, Abdelaziz Soukri, Bouchra El Khalfi
    Foods.2024; 13(4): 586.     CrossRef
  • Determination of Antioxidant and Antimicrobial Activities of Cell-Free Supernatant (CFSKC27L) and Exopolysaccharide (EPSKC27L) obtained from Ligilactobacillus salivarius KC27L
    Kübra Çelik, Zehranur Yuksekdag, Berat Çınar Acar, Filiz Kara
    Tekirdağ Ziraat Fakültesi Dergisi.2024; 21(4): 928.     CrossRef
  • Limosilactobacillus fermentum MYSY8, a Potential Probiotic Isolate from Fermented Rice Beverage for the Control of Microsporum canis
    Padur Ramachandra Vanitha, Divyashree Shivakumar, Shruthi Basavaraj, Adithi Gunduraj, Dhanuja Janardanachar, Deepthi BV, Marikunte Yanjarappa Sreenivasa
    Food Biotechnology.2024; 38(3): 314.     CrossRef
  • Multivariate analysis of structural and functional properties of fibres from apple pomace using different extraction methods
    Rusli Fidriyanto, Brij Pal Singh, K. M. Manju, Yantyati Widyastuti, Gunjan Goel
    Food Production, Processing and Nutrition.2023;[Epub]     CrossRef
  • Antifungal activity of probiotic strain Lactiplantibacillus plantarum MYSN7 against Trichophyton tonsurans
    P. R. Vanitha, Rakesh Somashekaraiah, S. Divyashree, Indranil Pan, M. Y. Sreenivasa
    Frontiers in Microbiology.2023;[Epub]     CrossRef
  • Synergistic combination of malic acid with sodium hypochlorite impairs biofilm of Cronobacter sakazakii
    Rajni Chauhan, Savita Kumari, Gunjan Goel, Wamik Azmi
    LWT.2022; 155: 112902.     CrossRef
  • Antibacterial and Antibiofilm Effect of Cell-Free Supernatant of Lactobacillus brevis KCCM 202399 Isolated from Korean Fermented Food against Streptococcus mutans KCTC 5458
    Jong Ha Kim, Hye Ji Jang, Na-Kyoung Lee, Hyun-Dong Paik
    Journal of Microbiology and Biotechnology.2022; 32(1): 56.     CrossRef
  • Selection of a Potential Synbiotic against Cronobacter sakazakii
    ALFRED KE, VALERIA R. PARREIRA, JEFFREY M. FARBER, LAWRENCE GOODRIDGE
    Journal of Food Protection.2022; 85(9): 1240.     CrossRef
  • Black cherry fruit as a source of probiotic candidates with antimicrobial and antibiofilm activities against Salmonella
    S. Divyashree, P.G Anjali, B.V. Deepthi, Rakesh Somashekaraiah, Walid Mottawea, Riadh Hammami, M.Y. Sreenivasa
    South African Journal of Botany.2022; 150: 861.     CrossRef
  • Anti-biofilm effect of the cell-free supernatant of probiotic Saccharomyces cerevisiae against Listeria monocytogenes
    Yeon Jin Kim, Hwan Hee Yu, Ye Ji Song, Yeong Jin Park, Na-Kyoung Lee, Hyun-Dong Paik
    Food Control.2021; 121: 107667.     CrossRef
  • Probiotic properties of Lactobacillus casei – MYSRD 108 and Lactobacillus plantarum-MYSRD 71 with potential antimicrobial activity against Salmonella paratyphi
    S. Divyashree, P.G. Anjali, Rakesh Somashekaraiah, M.Y. Sreenivasa
    Biotechnology Reports.2021; 32: e00672.     CrossRef
  • Intestinal microbiota and inflammatory bowel diseases
    Chang Soo Eun
    Journal of the Korean Medical Association.2021; 64(9): 588.     CrossRef
  • Current and Future Perspectives on the Role of Probiotics, Prebiotics, and Synbiotics in Controlling Pathogenic Cronobacter Spp. in Infants
    Alfred Ke, Valeria R. Parreira, Lawrence Goodridge, Jeffrey M. Farber
    Frontiers in Microbiology.2021;[Epub]     CrossRef
  • Impairment of Cronobacter sakazakii and Listeria monocytogenes biofilms by cell-free preparations of lactobacilli of goat milk origin
    Niharika Singh, Ravinder Kaur, Brij Pal Singh, Namita Rokana, Gunjan Goel, Anil Kumar Puniya, Harsh Panwar
    Folia Microbiologica.2020; 65(1): 185.     CrossRef
  • The Battle of Probiotics and Their Derivatives Against Biofilms


    Abolfazl Barzegari, Keyvan Kheyrolahzadeh, Seyed Mahdi Hosseiniyan Khatibi, Simin Sharifi, Mohammad Yousef Memar, Sepideh Zununi Vahed
    Infection and Drug Resistance.2020; Volume 13: 659.     CrossRef
  • Postbiotics against Pathogens Commonly Involved in Pediatric Infectious Diseases
    Anastasia Mantziari, Seppo Salminen, Hania Szajewska, Jeadran Nevardo Malagón-Rojas
    Microorganisms.2020; 8(10): 1510.     CrossRef
  • 9,515 View
  • 306 Download
  • 17 Web of Science
  • 17 Crossref
Close layer
IBD
The novel latex agglutination turbidimetric immunoassay system for simultaneous measurements of calprotectin and hemoglobin in feces
Sakiko Hiraoka, Shiho Takashima, Toshihiro Inokuchi, Asuka Nakarai, Masahiro Takahara, Keita Harada, Yasuhiro Seki, Katsunori Watanabe, Jun Kato, Hiroyuki Okada
Intest Res 2019;17(2):202-209.   Published online December 14, 2018
DOI: https://doi.org/10.5217/ir.2018.00086
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Background/Aims
Fecal calprotectin (Fcal) as well as the fecal immunochemical test (FIT) are useful biomarkers for detecting activity and mucosal healing in inflammatory bowel diseases. Here, we report the performance of simultaneous measurements of Fcal and FIT for ulcerative colitis (UC) patients using the newly-developed latex agglutination turbidimetric immunoassay (LATIA) system.
Methods
Fcal and hemoglobin were measured by the LATIA system in 152 UC patients who underwent colonoscopy. Fcal was also quantified with a conventional enzyme-linked immunosorbent assay (ELISA). Fecal markers were evaluated in conjunction with the mucosal status of UC, which was assessed via the Mayo endoscopic subscore (MES) classification.
Results
The LATIA system could quantify calprotectin and hemoglobin simultaneously with the same fecal samples within 10 minutes. The values of the Fcal-LATIA closely correlated with those of the Fcal-ELISA (Spearman rank correlation coefficient, r=0.84; P<0.0001). The values of Fcal for each assay and the FIT all significantly correlated with the MESs (Spearman rank correlation coefficient, Fcal-LATIA: r=0.58, Fcal-ELISA: r=0.55, and FIT: r=0.72). The mucosal healing predictability (determined by an MES of 0 alone) of the Fcal-LATIA, Fcal-ELISA, and FIT-LATIA with the cutoffs determined by receiver operating characteristic curve analysis was 0.79, 0.78, and 0.92 for sensitivity, respectively, and 0.78, 0.69, and 0.73 for specificity, respectively.
Conclusions
The performance of the novel Fcal-LATIA was equivalent to that of the conventional Fcal assay. Simultaneous measurements with FITs would promote the clinical relevance of fecal biomarkers in UC.

Citations

Citations to this article as recorded by  
  • Systematic scoping review: Use of the faecal immunochemical test residual buffer to enhance colorectal cancer screening
    Timothy McAuliffe, Joseph C. Anderson, Robin J. Larson, Douglas J. Robertson
    Alimentary Pharmacology & Therapeutics.2024; 59(9): 1033.     CrossRef
  • Evaluation of a faecal calprotectin method using the OC-SENSOR PLEDIA
    Shane O’Driscoll, Carolyn Piggott, Sally C. Benton
    Clinical Chemistry and Laboratory Medicine (CCLM).2022; 60(6): 901.     CrossRef
  • International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases
    Ferdinando D'Amico, David T. Rubin, Paulo Gustavo Kotze, Fernando Magro, Britta Siegmund, Taku Kobayashi, Pablo A. Olivera, Peter Bossuyt, Lieven Pouillon, Edouard Louis, Eugeni Domènech, Subrata Ghosh, Silvio Danese, Laurent Peyrin‐Biroulet
    United European Gastroenterology Journal.2021; 9(4): 451.     CrossRef
  • Faecal Calprotectin in Assessment of Mucosal Healing in Adults with Inflammatory Bowel Disease: A Meta-Analysis
    Mariusz A. Bromke, Katarzyna Neubauer, Radosław Kempiński, Małgorzata Krzystek-Korpacka
    Journal of Clinical Medicine.2021; 10(10): 2203.     CrossRef
  • Leucine-rich alpha-2 glycoprotein as a marker of mucosal healing in inflammatory bowel disease
    Eriko Yasutomi, Toshihiro Inokuchi, Sakiko Hiraoka, Kensuke Takei, Shoko Igawa, Shumpei Yamamoto, Masayasu Ohmori, Shohei Oka, Yasushi Yamasaki, Hideaki Kinugasa, Masahiro Takahara, Keita Harada, Masaki Furukawa, Kouichi Itoshima, Ken Okada, Fumio Otsuka,
    Scientific Reports.2021;[Epub]     CrossRef
  • Optimal Cutoff Level of Fecal Calprotectin for Detecting Small Bowel Inflammation in Crohn's Disease
    Eun Soo Kim
    Gut and Liver.2021; 15(5): 637.     CrossRef
  • Fecal calprotectin predicts complete mucosal healing in patients with ulcerative colitis: Systematic review and meta‑analysis
    Zhongsheng Cao, Chenglong Ye, Lunan Li, Xiaoge Geng, Wensheng Pan, Jiyong Jing
    World Academy of Sciences Journal.2021;[Epub]     CrossRef
  • Biochemical Biomarkers of Mucosal Healing for Inflammatory Bowel Disease in Adults
    Małgorzata Krzystek-Korpacka, Radosław Kempiński, Mariusz Bromke, Katarzyna Neubauer
    Diagnostics.2020; 10(6): 367.     CrossRef
  • Prostaglandin E-Major Urinary Metabolite Predicts Relapse in Patients With Ulcerative Colitis in Clinical Remission
    Natsuki Ishida, Kiichi Sugiura, Takahiro Miyazu, Satoshi Tamura, Satoshi Suzuki, Shinya Tani, Mihoko Yamade, Moriya Iwaizumi, Yasushi Hamaya, Satoshi Osawa, Takahisa Furuta, Ken Sugimoto
    Clinical and Translational Gastroenterology.2020; 11(12): e00289.     CrossRef
  • Prediction of treatment outcome and relapse in inflammatory bowel disease
    Jun Kato, Takeichi Yoshida, Sakiko Hiraoka
    Expert Review of Clinical Immunology.2019; 15(6): 667.     CrossRef
  • 8,072 View
  • 242 Download
  • 9 Web of Science
  • 10 Crossref
Close layer
IBD
The effect of vitamin D administration on inflammatory markers in patients with inflammatory bowel disease
Jae Chang Jun, Hyuk Yoon, Yoon Jin Choi, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee, Joo Sung Kim
Intest Res 2019;17(2):210-217.   Published online November 27, 2018
DOI: https://doi.org/10.5217/ir.2018.00081
AbstractAbstract PDFPubReaderePub
Background/Aims
The exact relationship between vitamin D deficiency and inflammatory bowel disease (IBD) remains unclear. We evaluated the effect of vitamin D3 administration on inflammatory responses and disease severity in patients with IBD.
Methods
We investigated the serum 25-hydroxyvitamin D3 [25-(OH)D] and C-reactive protein (CRP) levels and the partial Mayo score (PMS) in patients with IBD. Vitamin D3 was administered in patients with either vitamin D deficiency or insufficiency and CRP serum vitamin D levels and PMS were re-examined at 6 months of administration.
Results
In 88 patients with Crohn’s disease (CD), a negative correlation was found between serum vitamin D and CRP. In 178 patients with ulcerative colitis (UC), serum vitamin D showed no association with CRP or PMS. Serum vitamin D increased from 11.08±3.63 to 22.69±6.11 ng/mL in 29 patients with CD and from 11.45±4.10 to 24.20±6.61 ng/mL in 41 patients with UC who received vitamin D3 treatment (P<0.001 and P<0.001, respectively). In patients with CD, median ΔCRP was –0.24 in the normalized vitamin D group and –0.11 in the non-normalized group (P=0.308). In patients with UC, median ΔCRP was −0.01 in the normalized vitamin D group and 0.06 in the non-normalized group (P=0.359).
Conclusions
Although a negative correlation was found between serum vitamin D and CRP levels in patients with CD, administration of vitamin D did not improve the CRP level in patients with CD. In patients with UC, serum vitamin D level was unrelated to CRP or PMS.

Citations

Citations to this article as recorded by  
  • The use of vitamin D for patients with inflammatory bowel diseases
    Júlia Novaes Matias, Vinícius Marinho Lima, Giovanna Soares Nutels, Lucas Fornari Laurindo, Sandra Maria Barbalho, Ricardo de Alvares Goulart, Adriano Cressoni Araújo, Rodrigo Buzinaro Suzuki, Elen Landgraf Guiguer
    International Journal for Vitamin and Nutrition Research.2024; 94(1): 54.     CrossRef
  • The effect of vitamin D serum levels on the values of C-reactive protein and fecal calprotectin in patients with ulcerative colitis in clinical remission
    Zarko Krnetic, Tijana Icin, Zeljka Savic, Olgica Latinovic Bosnjak, Vladimir Vracaric, Dimitrije Damjanov, Tatiana Jocic, Radoslav Pejin, Nebojsa Janjic
    Vojnosanitetski pregled.2024; 81(10): 619.     CrossRef
  • Low Vitamin K and Vitamin D Dietary Intake in Patients with Inflammatory Bowel Diseases
    Filippo Vernia, Giorgia Burrelli Scotti, Noemi Sara Bertetti, Giuseppe Donato, Stefano Necozione, Piero Vernia, Nadia Pallotta
    Nutrients.2023; 15(7): 1678.     CrossRef
  • High Risk of Fractures Within 7 Years of Diagnosis in Asian Patients With Inflammatory Bowel Diseases
    Hyung Jin Ahn, Ye-Jee Kim, Ho-Su Lee, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Beom-Jun Kim, Sang Hyoung Park
    Clinical Gastroenterology and Hepatology.2022; 20(5): e1022.     CrossRef
  • High Dose Intramuscular Vitamin D3 Supplementation Impacts the Gut Microbiota of Patients With Clostridioides Difficile Infection
    Sang Hoon Lee, Han-Ki Park, Chang Don Kang, Dae Hee Choi, Sung Chul Park, Jin Myung Park, Seung-Joo Nam, Gi Bong Chae, Kyoung yul Lee, Hyunseok Cho, Sung Joon Lee
    Frontiers in Cellular and Infection Microbiology.2022;[Epub]     CrossRef
  • Influence of Severe Vitamin D Deficiency on the Clinical Course of Inflammatory Bowel Disease
    Nam Seok Ham, Sung Wook Hwang, Eun Hye Oh, Jeongseok Kim, Ho-Su Lee, Sang Hyoung Park, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang
    Digestive Diseases and Sciences.2021; 66(2): 587.     CrossRef
  • Effects of a Single Oral Megadose of Vitamin D3 on Inflammation and Oxidative Stress Markers in Overweight and Obese Women: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
    Laine de Carvalho Guerra Pessoa Mamede, Rafaela Lira Formiga Cavalcanti de Lima, Alexandre Sérgio Silva, João Carlos Lima Rodrigues Pita, Nadjeanny Ingrid Galdino Gomes, Elisama Araújo de Sena, Rhayra Priscila Moraes Nobrega, João Otávio Scarano Alcântara
    Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2021; Volume 14: 525.     CrossRef
  • The 25(OH)D3, but Not 1,25(OH)2D3 Levels Are Elevated in IBD Patients Regardless of Vitamin D Supplementation and Do Not Associate with Pain Severity or Frequency
    Anna Zielińska, Aleksandra Sobolewska-Włodarczyk, Maria Wiśniewska-Jarosińska, Anita Gąsiorowska, Jakub Fichna, Maciej Sałaga
    Pharmaceuticals.2021; 14(3): 284.     CrossRef
  • The effects of consuming a low-fat yogurt fortified with nano encapsulated vitamin D on serum pro-oxidant-antioxidant balance (PAB) in adults with metabolic syndrome; a randomized control trial
    Niloofar Taghizadeh, Payam Sharifan, Mansoureh Sadat Ekhteraee Toosi, Fatemeh Najar Sedgh Doust, Susan Darroudi, Asma Afshari, Mitra Rezaie, Mohamad Safarian, Hassan Vatanparast, Saeed Eslami, Hamideh Ghazizadeh, Zahra Khorasanchi, Mohammad Bagherniya, Go
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2021; 15(6): 102332.     CrossRef
  • Vitamin D and inflammatory bowel disease: what do we know so far?
    Antonio María Caballero Mateos, Raúl Vicente Olmedo-Martín, Amparo Roa-Colomo, María del Mar Díaz Alcázar, Manuel Valenzuela Barranco
    Revista Española de Enfermedades Digestivas.2020;[Epub]     CrossRef
  • Inflammatory Bowel Disease and Vitamin D
    Ki Bae Kim, Hyoung Woo Kim, Jun Su Lee, Soon Man Yoon
    The Korean Journal of Gastroenterology.2020; 76(6): 275.     CrossRef
  • Vitamin D in Inflammatory Bowel Disease: Biological, Clinical and Therapeutic Aspects
    Raúl Vicente Olmedo-Martín, Inmaculada González-Molero, Gabriel Olveira, Víctor Amo-Trillo, Miguel Jiménez-Pérez
    Current Drug Metabolism.2019; 20(5): 390.     CrossRef
  • Intraluminal Farnesol and Farnesal in the Mealworm's Alimentary Canal: An Unusual Storage Site Uncovering Hidden Eukaryote Ca2+-Homeostasis-Dependent “Golgicrine” Activities
    Arnold De Loof, Liliane Schoofs
    Frontiers in Endocrinology.2019;[Epub]     CrossRef
  • 7,043 View
  • 220 Download
  • 15 Web of Science
  • 13 Crossref
Close layer
IBD
Individualized treatment based on CYP3A5 single-nucleotide polymorphisms with tacrolimus in ulcerative colitis
Shinji Okabayashi, Taku Kobayashi, Eiko Saito, Takahiko Toyonaga, Ryo Ozaki, Shintaro Sagami, Masaru Nakano, Junichi Tanaka, Keiji Yagisawa, Satoshi Kuronuma, Osamu Takeuchi, Toshifumi Hibi
Intest Res 2019;17(2):218-226.   Published online February 7, 2019
DOI: https://doi.org/10.5217/ir.2018.00117
AbstractAbstract PDFPubReaderePub
Background/Aims
The pharmacokinetics of tacrolimus (TAC) is known to be largely influenced by single-nucleotide polymorphisms (SNPs) in CYP3A5. Patients starting TAC require careful dose adjustment, owing to the wide range of optimal dosages, depending on their CYP3A5 expression status. Here, we evaluated whether individualization of TAC dosages based on CYP3A5 SNPs would improve its therapeutic efficacy in ulcerative colitis.
Methods
Twenty-one patients were prospectively treated, with their initial dosage adjusted according to their CYP3A5 status (0.1, 0.15, and 0.2 mg/kg/day for CYP3A5*3/*3, CYP3A5*1/*3, and CYP3A5*1/*1, respectively). Their clinical outcomes were compared with those of patients treated with a fixed dose (0.1 mg/kg/day).
Results
The first blood trough level of CYP3A5 expressors, CYP3A5*1/*3 or CYP3A5*1/*1, and the overall rate in achieving the target blood trough level within a week in the individualized-dose group were significantly higher than those in the fixed-dose group (5.15±2.33 ng/mL vs. 9.63±0.79 ng/mL, P=0.035 and 12.5% vs. 66.7%, P=0.01). The remission rate at 2 weeks in the expressors was as high as that in the nonexpressors, CYP3A5*3/*3, in the individualized-dose group.
Conclusions
Individualized TAC treatment is effective against ulcerative colitis regardless of the CYP3A5 genotype.

Citations

Citations to this article as recorded by  
  • The impact of cytochrome P450 3A genetic polymorphisms on tacrolimus pharmacokinetics in ulcerative colitis patients
    Maizumi Furuse, Shuhei Hosomi, Yu Nishida, Shigehiro Itani, Yuji Nadatani, Shusei Fukunaga, Koji Otani, Fumio Tanaka, Yasuaki Nagami, Koichi Taira, Noriko Kamata, Toshio Watanabe, Kenji Watanabe, Yasuhiro Fujiwara, Erika Cecchin
    PLOS ONE.2021; 16(4): e0250597.     CrossRef
  • Advances in research of tacrolimus for treatment of inflammatory bowel disease
    Jing-Jing Wang, Yi-Hong Fan
    World Chinese Journal of Digestology.2019; 27(13): 842.     CrossRef
  • 7,136 View
  • 147 Download
  • 1 Web of Science
  • 2 Crossref
Close layer
IBD
Abdominal ultrasonography with color Doppler analysis in the assessment of ileal Crohn’s disease: comparison with magnetic resonance enterography
Antonio Carlos da Silva Moraes, Glycia de Freitas Moraes, Antonio Luis Eiras de Araújo, Ronir Raggio Luiz, Celeste Elia, Antonio Jose Carneiro, Heitor Siffert Pereira de Souza
Intest Res 2019;17(2):227-236.   Published online April 10, 2019
DOI: https://doi.org/10.5217/ir.2018.00124
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Background/Aims
Consistently defining disease activity remains a critical challenge in the follow-up of patients with Crohn’s disease (CD). We investigated the potential applicability of abdominal ultrasonography with color Doppler (USCD) analysis for the detection of morphological alterations and inflammatory activity in CD.
Methods
Forty-three patients with CD ileitis/ileocolitis were evaluated using USCD analysis with measurements obtained on the terminal ileum and right colon. Sonographic parameters included wall thickening, stricture, hyperemia, presence of intra-abdominal mass, and fistulas. Patients were evaluated for the clinical activity (Harvey-Bradshaw Index [HBI]), fecal calprotectin (FC) and C-reactive protein (CRP). The USCD performance was assessed using magnetic resonance enterography (MRE) as a criterion standard.
Results
Most measurements obtained with USCD matched the data generated with MRE; however, the agreement improved in clinically active patients where sensitivity, positive predictive value, and accuracy were >80%, considering wall thickening and hyperemia. Complications such as intestinal wall thickening, stricture formation, and hyperemia, were detected in the USCD analysis with moderate agreement with MRE. The best agreement with the USCD analysis was obtained in regard to FC, where the sensitivity, positive predictive value, and accuracy were >70%. The overall performance of USCD was superior to that of HBI, FC and CRP levels, particularly when considering thickening, stricture, and hyperemia parameters.
Conclusions
USCD represents a practical noninvasive and low-cost tool for evaluating patients with ileal or ileocolonic disease, particularly in clinically active CD. Therefore, USCD might become a useful asset in the follow-up of patients with CD.

Citations

Citations to this article as recorded by  
  • Diagnostic Accuracy of Intestinal Ultrasound in the Detection of Intra-Abdominal Complications in Crohn’s Disease: A Systematic Review and Meta-Analysis
    Maarten J Pruijt, Floris A E de Voogd, Nahid S M Montazeri, Faridi S van Etten-Jamaludin, Geert R D’Haens, Krisztina B Gecse
    Journal of Crohn's and Colitis.2024; 18(6): 958.     CrossRef
  • Comparative study between ultrasound and MR enterography in evaluation of Crohn’s disease
    Nada Sayed Mahdy, Sahar Mohammed El-Gaafary, Khaled Hamdy Abdel Mageed, Khaled A. Ali Shehata, Maha Ahmed Sayed AbdelKarim, Essam Mohamed Abdulhafiz
    Egyptian Journal of Radiology and Nuclear Medicine.2024;[Epub]     CrossRef
  • Could ultrasound alone substitute MR imaging in evaluation of Crohn’s disease complications?
    Hany El-Assaly, Asmaa Abdel Baky Mohamed, Hesham Adel Abdel Fattah Mustafa
    Egyptian Journal of Radiology and Nuclear Medicine.2024;[Epub]     CrossRef
  • Radiology plus ileocolonoscopy versus radiology alone in Crohn’s disease: prognosis prediction and mutual agreement
    Hye Kyung Hyun, Jongwook Yu, Eun Ae Kang, Jihye Park, Soo Jung Park, Jae Jun Park, Tae Il Kim, Won Ho Kim, Jae Hee Cheon
    The Korean Journal of Internal Medicine.2022; 37(3): 567.     CrossRef
  • Comparison of Diagnostic Performance of Ultrasonography and Magnetic Resonance Enterography in the Assessment of Active Bowel Lesions in Patients with Crohn’s Disease: A Systematic Review and Meta-Analysis
    Da In Lee, Myung-Won You, So Hyun Park, Mirinae Seo, Seong Jin Park
    Diagnostics.2022; 12(8): 2008.     CrossRef
  • Fistulizing Crohn's disease
    Amy L. Lightner, Jean H. Ashburn, Mantaj S. Brar, Michele Carvello, Pramodh Chandrasinghe, Anthony de Buck van Overstraeten, Phillip R. Fleshner, Gaetano Gallo, Paulo Gustavo Kotze, Stefan D. Holubar, Lillian M. Reza, Antonino Spinelli, Scott A. Strong, P
    Current Problems in Surgery.2020; 57(11): 100808.     CrossRef
  • 7,850 View
  • 141 Download
  • 6 Web of Science
  • 6 Crossref
Close layer
IBD
Influence of anti-tumor necrosis factor-alpha therapy to pregnant inflammatory bowel disease women and their children’s immunity
Ko Eun Lee, Sung-Ae Jung, Sang Hyoung Park, Chang Mo Moon, So Yeon Shim, Eun Soo Kim, Su Jin Cho, Seong-Eun Kim, Kwang Bum Cho, Suk-Kyun Yang
Intest Res 2019;17(2):237-243.   Published online February 8, 2019
DOI: https://doi.org/10.5217/ir.2018.00071
AbstractAbstract PDFPubReaderePub
Background/Aims
The onset of inflammatory bowel disease (IBD) usually occurs at young age, and therefore, women IBD patients experience pregnancy during their disease progression. Recently, the use of anti-tumor necrosis factor-α (anti-TNF-α) has been rapidly increasing. The aim of this study was to evaluate pregnancy related outcomes in women with IBD who were treated with anti-TNF-α during pregnancy and immunity of their children.
Methods
Korean women with IBD who had been treated with anti-TNF-α during pregnancy had been enrolled. Medical records were reviewed and a survey was performed for each patient. For the patients who agreed on additional examination for their children, children’s growth, medical history and antibody to hepatitis B surface antigen (anti-HBs) titer were checked.
Results
All 18 patients had been diagnosed with Crohn’s disease. There was not any case of preterm delivery, low birth-weight infant, congenital anomaly, nor stillbirth. All 12 children had followed the regular vaccination schedule for hepatitis B and 4 of them showed negative results for anti-HBs. After the 1 booster vaccination, all children demonstrated seroconversion. Regarding live vaccines, 4 children had bacillus Calmette-Guerin and 4 had rotavirus vaccine before 6 months, without any specific side effects.
Conclusions
This was the first study of immunity of the children born from IBD women who had been treated with anti-TNF-α medication during their pregnancy. IBD women had comparable pregnancy outcomes with the general women population, suggesting that the disease activity rather than the administered medication would be more important in healthy pregnancy. Considering the history of vaccination and anti-HBs titers, immunity seems to be intact in the children.

Citations

Citations to this article as recorded by  
  • Safety of Rotavirus Vaccination in Infants That Were Exposed to Biologics In Utero: A Systematic Review
    Trevor L Schell, Lucas Fass, Mary E Hitchcock, Francis A Farraye, Mary S Hayney, Sumona Saha, Freddy Caldera
    Inflammatory Bowel Diseases.2024;[Epub]     CrossRef
  • 2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases
    Anne R. Bass, Eliza Chakravarty, Elie A. Akl, Clifton O. Bingham, Leonard Calabrese, Laura C. Cappelli, Sindhu R. Johnson, Lisa F. Imundo, Kevin L. Winthrop, Reuben J. Arasaratnam, Lindsey R. Baden, Roberta Berard, S. Louis Bridges, Jonathan T. L. Cheah,
    Arthritis & Rheumatology.2023; 75(3): 333.     CrossRef
  • 2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases
    Anne R. Bass, Eliza Chakravarty, Elie A. Akl, Clifton O. Bingham, Leonard Calabrese, Laura C. Cappelli, Sindhu R. Johnson, Lisa F. Imundo, Kevin L. Winthrop, Reuben J. Arasaratnam, Lindsey R. Baden, Roberta Berard, S. Louis Bridges, Jonathan T. L. Cheah,
    Arthritis Care & Research.2023; 75(3): 449.     CrossRef
  • Society for Maternal-Fetal Medicine Consult Series #64: Systemic lupus erythematosus in pregnancy
    Robert Silver, Sabrina Craigo, Flint Porter, Sarah S. Osmundson, Jeffrey A. Kuller, Mary E. Norton
    American Journal of Obstetrics and Gynecology.2023; 228(3): B41.     CrossRef
  • Vaccines in Children Exposed to Biological AgentsIn Uteroand/or During Breastfeeding: Are They Effective and Safe?
    Javier P Gisbert, María Chaparro
    Journal of Crohn's and Colitis.2023; 17(6): 995.     CrossRef
  • Vaccination for rheumatic diseases: Current issues (based on ACR guidelines)
    B. S. Belov, N. V. Muravyeva, E. L. Nasonov
    Rheumatology Science and Practice.2023; 61(2): 151.     CrossRef
  • Pregnancy Outcomes Associated With Biologic Agent Exposure in Patients With Several Rheumatic Diseases and Inflammatory Bowel Diseases
    Soo Min Ahn, Young Bin Joo, Yun Jin Kim, So-Young Bang, Hye-Soon Lee
    Journal of Korean Medical Science.2023;[Epub]     CrossRef
  • Modern Ideas about Vaccination of Patients with Rheumatic Diseases: the View of ACR Experts
    B. S. Belov, N. V. Muravyeva
    Antibiotics and Chemotherapy.2023; 68(5-6): 77.     CrossRef
  • Suboptimal Vaccination Administration in Mothers With Inflammatory Bowel Disease and Their Biologic-Exposed Infants
    Helene Chiarella-Redfern, Sangmin Lee, Bellal Jubran, Nastaran Sharifi, Remo Panaccione, Cora Constantinescu, Eric I Benchimol, Cynthia H Seow
    Inflammatory Bowel Diseases.2022; 28(1): 79.     CrossRef
  • A systematic review of live vaccine outcomes in infants exposed to biologic disease modifying anti-rheumatic drugs in utero
    Bethan Goulden, Nicole Chua, Elaine Parker, Ian Giles
    Rheumatology.2022; 61(10): 3902.     CrossRef
  • The Risk of Adverse Neonatal Outcomes With Maternal Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
    Kristel K Leung, Parul Tandon, Vivek Govardhanam, Cynthia Maxwell, Vivian Huang
    Inflammatory Bowel Diseases.2021; 27(4): 550.     CrossRef
  • The Influence of Disease Activity on Pregnancy Outcomes in Women With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
    Min-A Kim, Young-Han Kim, Jaeyoung Chun, Hye Sun Lee, Soo Jung Park, Jae Hee Cheon, Tae Il Kim, Won Ho Kim, Jae Jun Park
    Journal of Crohn's and Colitis.2021; 15(5): 719.     CrossRef
  • Biologics During Pregnancy and Breastfeeding Among Women With Rheumatic Diseases: Safety Clinical Evidence on the Road
    Asmaa Beltagy, Azin Aghamajidi, Laura Trespidi, Wally Ossola, Pier Luigi Meroni
    Frontiers in Pharmacology.2021;[Epub]     CrossRef
  • ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease
    T Kucharzik, P Ellul, T Greuter, J F Rahier, B Verstockt, C Abreu, A Albuquerque, M Allocca, M Esteve, F A Farraye, H Gordon, K Karmiris, U Kopylov, J Kirchgesner, E MacMahon, F Magro, C Maaser, L de Ridder, C Taxonera, M Toruner, L Tremblay, M Scharl, N
    Journal of Crohn's and Colitis.2021; 15(6): 879.     CrossRef
  • Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)—Part 1: Live Vaccines
    Eric I. Benchimol, Frances Tse, Matthew W. Carroll, Jennifer C. deBruyn, Shelly A. McNeil, Anne Pham-Huy, Cynthia H. Seow, Lisa L. Barrett, Talat Bessissow, Nicholas Carman, Gil Y. Melmed, Otto G. Vanderkooi, John K. Marshall, Jennifer L. Jones
    Gastroenterology.2021; 161(2): 669.     CrossRef
  • Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)—Part 1: Live Vaccines
    Eric I Benchimol, Frances Tse, Matthew W Carroll, Jennifer C deBruyn, Shelly A McNeil, Anne Pham-Huy, Cynthia H Seow, Lisa L Barrett, Talat Bessissow, Nicholas Carman, Gil Y Melmed, Otto G Vanderkooi, John K Marshall, Jennifer L Jones
    Journal of the Canadian Association of Gastroenterology.2021; 4(4): e59.     CrossRef
  • Systematic review with meta‐analysis: risk of adverse pregnancy‐related outcomes in inflammatory bowel disease
    Parul Tandon, Vivek Govardhanam, Kristel Leung, Cynthia Maxwell, Vivian Huang
    Alimentary Pharmacology & Therapeutics.2020; 51(3): 320.     CrossRef
  • Safety and Optimal Timing of BCG Vaccination in Infants Born to Mothers Receiving Anti-TNF Therapy for Inflammatory Bowel Disease
    Sang Hyoung Park, Hyo Jong Kim, Chang Kyun Lee, Eun Mi Song, Sang-Bum Kang, Byung Ik Jang, Eun Soo Kim, Kyeong Ok Kim, Yoo Jin Lee, Eun Young Kim, Yun Jin Jung, Soo-Kyung Park, Dong Il Park, Byong Duk Ye, Sung-Ae Jung, Suk-Kyun Yang
    Journal of Crohn's and Colitis.2020; 14(12): 1780.     CrossRef
  • Intrauterine Exposure to Biologics in Inflammatory Autoimmune Diseases: A Systematic Review
    N. Ghalandari, R. J. E. M. Dolhain, J. M. W. Hazes, E. P. van Puijenbroek, M. Kapur, H. J. M. J. Crijns
    Drugs.2020; 80(16): 1699.     CrossRef
  • 8,267 View
  • 224 Download
  • 17 Web of Science
  • 19 Crossref
Close layer
IBD
The impact of corticosteroid use on inpatients with inflammatory bowel disease and positive polymerase chain reaction for Clostridium difficile
Huei-Wen Lim, Isaiah P. Schuster, Ramona Rajapakse, Farah Monzur, Sundas Khan, Keith Sultan
Intest Res 2019;17(2):244-252.   Published online February 12, 2019
DOI: https://doi.org/10.5217/ir.2018.00101
AbstractAbstract PDFPubReaderePub
Background/Aims
Optimal management of inflammatory bowel disease (IBD) with concomitant Clostridium difficile infection (CDI) is controversial, especially when CDI diagnosis is made by polymerase chain reaction (PCR) testing, which may reflect colonization without infection.
Methods
We performed a multicenter review of all inpatients with IBD and PCR diagnosed CDI. Outcomes included length of stay, 30- and 90-day readmission, colectomy during admission and within 3 months, intensive care unit (ICU) admission, CDI relapse and death for patients who received corticosteroid (CS) after CDI diagnosis versus those that did not. Propensity-adjusted regression analysis of outcomes based on CS usage was performed.
Results
We identified 177 IBD patients with CDI, 112 ulcerative colitis and 65 Crohn’s disease. For IBD overall, CS after CDI diagnosis was associated with prolonged hospitalization (5.5 days: 95% confidence interval [CI], 1.5–9.6 days; P=0.008), higher colectomy rate within 3 months (odds ratio [OR], 5.5; 95% CI, 1.1–28.2; P=0.042) and more frequent ICU admissions (OR, 7.8; 95% CI, 1.5–41.6; P=0.017) versus no CS. CS use post-CDI diagnosis in UC patients was associated with prolonged hospitalization (6.2 days: 95% CI, 0.4– 12.0 days; P=0.036) and more frequent ICU admissions (OR, 7.4; 95% CI, 1.1–48.7; P=0.036).
Conclusions
CS use among IBD inpatients with CDI diagnosed by PCR is associated with poorer outcomes and would seem to reinforce the importance of C. difficile toxin assay to help distinguish colonization from infection. This adverse effect appears more prominent among those with UC.

Citations

Citations to this article as recorded by  
  • Clostridioides difficile infection in inflammatory bowel disease: a clinical review
    Mengjun Tang, Chunhua Wang, Ying Xia, Jian Tang, Jiao Wang, Liang Shen
    Expert Review of Anti-infective Therapy.2024; 22(5): 297.     CrossRef
  • The Current Knowledge on Clostridioides difficile Infection in Patients with Inflammatory Bowel Diseases
    Alina Boeriu, Adina Roman, Crina Fofiu, Daniela Dobru
    Pathogens.2022; 11(7): 819.     CrossRef
  • Korean Association for the Study of Intestinal Diseases guidance for clinical practice of adult inflammatory bowel disease during the coronavirus disease 2019 pandemic: expert consensus statements
    Yong Eun Park, Yoo Jin Lee, Ji Young Chang, Hyun Joo Song, Duk Hwan Kim, Young Joo Yang, Byung Chang Kim, Jae Gon Lee, Hee Chan Yang, Miyoung Choi, Seong-Eun Kim, Seung-Jae Myung
    Intestinal Research.2022; 20(4): 431.     CrossRef
  • KASID Guidance for Clinical Practice Management of Adult Inflammatory Bowel Disease during the COVID-19 Pandemic: Expert Consensus Statement
    Yong Eun Park, Yoo Jin Lee, Ji Young Chang, Hyun Joo Song, Duk Hwan Kim, Young Joo Yang, Byung Chang Kim, Jae Gon Lee, Hee Chan Yang, Miyoung Choi, Seong-Eun Kim, Seung-Jae Myung
    The Korean Journal of Gastroenterology.2021; 78(2): 105.     CrossRef
  • 8,924 View
  • 170 Download
  • 4 Web of Science
  • 4 Crossref
Close layer
Colorectal neoplasia
Development and validation of a scoring system for advanced colorectal neoplasm in young Korean subjects less than age 50 years
Ji Yeon Kim, Sungkyoung Choi, Taesung Park, Seul Ki Kim, Yoon Suk Jung, Jung Ho Park, Hong Joo Kim, Yong Kyun Cho, Chong Il Sohn, Woo Kyu Jeon, Byung Ik Kim, Kyu Yong Choi, Dong Il Park
Intest Res 2019;17(2):253-264.   Published online November 20, 2018
DOI: https://doi.org/10.5217/ir.2018.00062
AbstractAbstract PDFPubReaderePub
Background/Aims
Colorectal cancer incidence among patients aged ≤50 years is increasing. This study aimed to develop and validate an advanced colorectal neoplasm (ACRN) screening model for young adults aged <50 years in Korea.
Methods
This retrospective cross-sectional study included 59,575 consecutive asymptomatic Koreans who underwent screening colonoscopy between 2003 and 2012 at a single comprehensive health care center. Young Adult Colorectal Screening (YCS) score was developed as an optimized risk stratification model for ACRN using multivariate analysis and was internally validated. The predictive power and diagnostic performance of YCS score was compared with those of Asia-Pacific Colorectal Screening (APCS) and Korean Colorectal Screening (KCS) scores.
Results
41,702 and 17,873 subjects were randomly allocated into the derivation and validation cohorts, respectively, by examination year. ACRN prevalence was 0.9% in both cohorts. YCS score comprised sex, age, alcohol, smoking, obesity, glucose metabolism abnormality, and family history of CRC, with score ranges of 0 to 10. In the validation cohort, ACRN prevalence was 0.6% in the low-risk tier (score, 0–4), 1.5% in the moderate-risk tier (score, 5–7), and 3.4% in the high-risk tier (score, 8–10). ACRN risk increased 2.5-fold (95%CI, 1.8–3.4) in the moderate-risk tier and 5.8-fold (95%CI, 3.4–9.8) in the high-risk tier compared with the low-risk tier. YCS score identified better balanced accuracy (53.9%) than APCS (51.5%) and KCS (50.7%) scores and had relatively good discriminative power (area under the curve=0.660).
Conclusions
YCS score based on clinical and laboratory risk factors was clinically effective and beneficial for predicting ACRN risk and targeting screening colonoscopy in adults aged <50 years.

Citations

Citations to this article as recorded by  
  • Performance of the Asia–Pacific Colorectal Screening score in stratifying the risk of advanced colorectal neoplasia: A meta‐analysis and systematic review
    Mai Ngoc Luu, Nhi Ai Trinh, Truc Le Thanh Tran, Thinh Phuong Dang, Toru Hiyama, Duc Trong Quach
    Journal of Gastroenterology and Hepatology.2024; 39(6): 1000.     CrossRef
  • Response to commentaries on “Performance of the Asia‐Pacific colorectal screening score in stratifying the risk of advanced colorectal neoplasia: A meta‐analysis and systematic review”
    MN Luu, DT Quach
    Journal of Gastroenterology and Hepatology.2024;[Epub]     CrossRef
  • Updated epidemiology of gastrointestinal cancers in East Asia
    Junjie Huang, Don Eliseo Lucero-Prisno, Lin Zhang, Wanghong Xu, Sunny H. Wong, Siew C. Ng, Martin C. S. Wong
    Nature Reviews Gastroenterology & Hepatology.2023; 20(5): 271.     CrossRef
  • From Algorithms to Clinical Utility: A Systematic Review of Individualized Risk Prediction Models for Colorectal Cancer
    Deborah Jael Herrera, Wessel van de Veerdonk, Daiane Maria Seibert, Moges Muluneh Boke, Claudia Gutiérrez-Ortiz, Nigus Bililign Yimer, Karen Feyen, Allegra Ferrari, Guido Van Hal
    Gastrointestinal Disorders.2023; 5(4): 549.     CrossRef
  • Emergence of a New Optical Marker for Colorectal Neoplasms: To What Extent Should We Accept It?
    Han Hee Lee
    Clinical Endoscopy.2022; 55(2): 315.     CrossRef
  • Is early-onset cancer an emerging global epidemic? Current evidence and future implications
    Tomotaka Ugai, Naoko Sasamoto, Hwa-Young Lee, Mariko Ando, Mingyang Song, Rulla M. Tamimi, Ichiro Kawachi, Peter T. Campbell, Edward L. Giovannucci, Elisabete Weiderpass, Timothy R. Rebbeck, Shuji Ogino
    Nature Reviews Clinical Oncology.2022; 19(10): 656.     CrossRef
  • Strategies for colorectal cancer screening and post-polypectomy surveillance for young adults under age 50
    Yoon Suk Jung
    Precision and Future Medicine.2021; 5(2): 69.     CrossRef
  • How to Choose the Optimal Bowel Preparation Regimen for Colonoscopy
    Ji Eun Na, Eun Ran Kim
    The Ewha Medical Journal.2021; 44(4): 122.     CrossRef
  • The Role of Diet and Lifestyle in Early-Onset Colorectal Cancer: A Systematic Review
    Marta Puzzono, Alessandro Mannucci, Simone Grannò, Raffaella Alessia Zuppardo, Andrea Galli, Silvio Danese, Giulia Martina Cavestro
    Cancers.2021; 13(23): 5933.     CrossRef
  • Association between waist circumference and risk of colorectal neoplasia in normal‐weight adults
    Yoon Suk Jung, Nam Hee Kim, Hyo‐Joon Yang, Soo‐Kyung Park, Jung Ho Park, Dong Il Park, Chong Il Sohn
    Journal of Gastroenterology and Hepatology.2020; 35(1): 43.     CrossRef
  • Risk prediction rule for advanced neoplasia on screening colonoscopy for average-risk individuals
    Ala I Sharara, Ali El Mokahal, Ali H Harb, Natalia Khalaf, Fayez S Sarkis, Mustapha M El-Halabi, Nabil M Mansour, Ahmad Malli, Robert Habib
    World Journal of Gastroenterology.2020; 26(37): 5705.     CrossRef
  • Risk Factors Associated With Young-Onset Colorectal Adenomas and Cancer: A Systematic Review and Meta-Analysis of Observational Research
    Genevieve Breau, Ursula Ellis
    Cancer Control.2020;[Epub]     CrossRef
  • Prevalence and risk factors of colorectal cancer in Asia
    Martin CS Wong, Hanyue Ding, Jingxuan Wang, Paul SF Chan, Junjie Huang
    Intestinal Research.2019; 17(3): 317.     CrossRef
  • 8,484 View
  • 164 Download
  • 12 Web of Science
  • 13 Crossref
Close layer
Endoscopy
Efficacy and safety of cold forceps polypectomy utilizing the jumbo cup: a prospective study
Hiroshi Hasegawa, Shigeki Bamba, Kenichiro Takahashi, Masaki Murata, Taketo Otsuka, Hiroshi Matsumoto, Takehide Fujimoto, Rie Osak, Hirotsugu Imaeda, Atsushi Nishida, Hiromitsu Ban, Ayano Sonoda, Osamu Inatomi, Masaya Sasaki, Mitsushige Sugimoto, Akira Andoh
Intest Res 2019;17(2):265-272.   Published online November 28, 2018
DOI: https://doi.org/10.5217/ir.2018.00103
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Background/Aims
There are few prospective studies on cold forceps polypectomy (CFP) using jumbo cup forceps. Therefore, we examined patients with diminutive polyps (5 mm or smaller) treated with CFP using jumbo cup forceps to achieve an adenoma-free colon and also assessed the safety of the procedure and the recurrence rate of missed or residual polyp after CFP by performing follow-up colonoscopy 1 year later.
Methods
We included patients with up to 5 adenomas removed at initial colonoscopy and analyzed data from a total of 361 patients with 573 adenomas. One-year follow-up colonoscopy was performed in 165 patients, at which 251 lesions were confirmed.
Results
The one-bite resection rate with CFP was highest for lesions 3 mm or smaller and decreased significantly with increasing lesion size. Post-procedural hemorrhage was observed in 1 of 573 lesions (0.17%). No perforation was noted. The definite recurrence rate was 0.8% (2/251 lesions). The probable recurrence rate, which was defined as recurrence in the same colorectal segment, was 17%. Adenoma-free colon was achieved in 55% of patients at initial resection. Multivariate analysis revealed that achievement of an adenoma-free colon was significantly associated with number of adenomas and years of endoscopic experience.
Conclusions
CFP using jumbo biopsy forceps was safe and showed a high one-bite resection rate for diminutive lesions of 3 mm or smaller. The low definite recurrence rate confirms the reliability of CFP using jumbo biopsy forceps. Number of adenomas and years of endoscopic experience were key factors in achieving an adenoma-free colon.

Citations

Citations to this article as recorded by  
  • Polypectomy for Diminutive and Small Colorectal Polyps
    Melissa Zarandi-Nowroozi, Roupen Djinbachian, Daniel von Renteln
    Gastrointestinal Endoscopy Clinics of North America.2022; 32(2): 241.     CrossRef
  • Cold Snare Resection of Colorectal Polyps: Updates and Recent Developments
    Roupen Djinbachian, Daniel von Renteln
    Current Treatment Options in Gastroenterology.2022; 20(3): 221.     CrossRef
  • Prospective multicenter study of the efficacy and safety of cold forceps polypectomy for ≤ 6-mm non-ampullary duodenal low-grade adenomas
    Hiromitsu Kanzaki, Joichiro Horii, Ryuta Takenaka, Hiroyuki Nakagawa, Kazuhiro Matsueda, Takao Tsuzuki, Masahide Kita, Yasushi Yamasaki, Takehiro Tanaka, Masaya Iwamuro, Seiji Kawano, Yoshiro Kawahara, Jun Tomoda, Hiroyuki Okada
    Endoscopy International Open.2022; 10(06): E712.     CrossRef
  • Endoscopic resection of local recurrences of diminutive polyps by cold forceps polypectomy
    Toshio Kuwai, Takuya Yamada, Tatsuya Toyokawa, Tomohiro Kudo, Naoki Esaka, Hajime Ohta, Haruhiro Yamashita, Yasuo Hosoda, Noriko Watanabe, Naohiko Harada
    Scandinavian Journal of Gastroenterology.2021; 56(3): 363.     CrossRef
  • How to Approach Small Polyps in Colon: Tips and Tricks
    Sultan Mahmood, Enrik John Aguila, Asad ur Rahman, Asim Shuja, Steven Bollipo
    Techniques and Innovations in Gastrointestinal Endoscopy.2021; 23(4): 328.     CrossRef
  • Risk factors for incomplete polyp resection during colonoscopy
    Weifeng Lao, Pankaj Prasoon, Gaoyang Cao, Lian Tat Tan, Sheng Dai, Giridhar Hanumappa Devadasar, Xuefeng Huang
    Laparoscopic, Endoscopic and Robotic Surgery.2021;[Epub]     CrossRef
  • Rates of Incomplete Resection of 1- to 20-mm Colorectal Polyps: A Systematic Review and Meta-Analysis
    Roupen Djinbachian, Ryma Iratni, Madeleine Durand, Paola Marques, Daniel von Renteln
    Gastroenterology.2020; 159(3): 904.     CrossRef
  • Child-Pugh B or C Cirrhosis Increases the Risk for Bleeding Following Colonoscopic Polypectomy
    Hosim Soh, Jaeyoung Chun, Seung Wook Hong, Seona Park, Yun Bin Lee, Hyun Jung Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jong Pil Im, Yoon Jun Kim, Joo Sung Kim, Jung-Hwan Yoon
    Gut and Liver.2020; 14(6): 755.     CrossRef
  • 9,783 View
  • 174 Download
  • 7 Web of Science
  • 8 Crossref
Close layer
Case Report
IBD
Remission of diffuse ulcerative duodenitis in a patient with ulcerative colitis after infliximab therapy: a case study and review of the literature
Yong-Sung Choi, Jong Kyu Kim, Wan Jung Kim, Mi-Jung Kim
Intest Res 2019;17(2):273-277.   Published online February 12, 2019
DOI: https://doi.org/10.5217/ir.2018.00122
AbstractAbstract PDFPubReaderePub
Although ulcerative colitis (UC) is confined to colonic and rectal mucosa in a continuous fashion, recent studies have also demonstrated the involvement of upper gastrointestinal tract as diagnostic endoscopy becomes more available and technically advanced. The pathogenesis of UC is not well established yet. It might be associated with an inappropriate response of host mucosal immune system to gut microflora. Although continuous and symmetric distribution of mucosal inflammation from rectum to colon is a typical pattern of UC, clinical feature and course of atypically distributed lesions in UC might also help us understand the pathogenesis of UC. Herein, we report a case of duodenal involvement of UC which successfully remitted after infliximab therapy. Endoscopic and pathologic findings before and after administration of anti-tumor necrosis factor suggest that the pathogenesis of upper gastrointestinal involvement of UC may be similar to that of colon involvement.

Citations

Citations to this article as recorded by  
  • Gastroduodenitis Associated with Active Ulcerative Colitis Treated with Infliximab: Different Clinical Course in the Colon and Gastroduodenal Lesions
    Tomoyuki Hayashi, Takeshi Terashima, Masaki Nishitani, Noriaki Orita, Masaki Miyazawa, Akihiro Seki, Hidetoshi Nakagawa, Kouki Nio, Noriho Iida, Shinya Yamada, Hajime Takatori, Tetsuro Shimakami, Taro Yamashita
    Internal Medicine.2024; 63(7): 929.     CrossRef
  • Severe Disease Activity May Predispose Patients to Post-colectomy Duodenitis Associated with Ulcerative Colitis
    Akira Sonoda, Naoki Yoshimura, Minako Sako, Soh Okano, Satoshi Saito, Masakazu Takazoe, Satomi Furukawa, Kinya Okamoto, Tetsuo Yamana, Hisateru Tachimori, Masayuki Fukata
    Internal Medicine.2024; 63(10): 1337.     CrossRef
  • Concurrent occurrence of ulcerative duodenitis and ulcerative colitis displaying unique responses to golimumab and ustekinumab
    Sho Masaki, Hajime Honjo, Masayuki Kurimoto, Natsuki Okai, Yasuo Otsuka, Yasuhiro Masuta, Ken Kamata, Kosuke Minaga, Masatoshi Kudo, Tomohiro Watanabe
    Clinical Journal of Gastroenterology.2024; 17(5): 854.     CrossRef
  • Upper Gastrointestinal Tract Involvement in Inflammatory Bowel Diseases: Histologic Clues and Pitfalls
    Bence Kővári, Rish K. Pai
    Advances in Anatomic Pathology.2022; 29(1): 2.     CrossRef
  • Mucosal lesions of the upper gastrointestinal tract in patients with ulcerative colitis: A review
    Yan Sun, Zhe Zhang, Chang-Qing Zheng, Li-Xuan Sang
    World Journal of Gastroenterology.2021; 27(22): 2963.     CrossRef
  • Clinical characteristics and prognosis of patients with ulcerative colitis that shows rectal sparing at initial diagnosis
    Yong-Sung Choi, Jong-Kyu Kim, Wan-Jung Kim
    World Journal of Gastrointestinal Endoscopy.2021; 13(9): 407.     CrossRef
  • Upper Gastrointestinal Manifestations of Inflammatory Bowel Disease
    Noam Harpaz, Alexandros D. Polydorides
    Surgical Pathology Clinics.2020; 13(3): 413.     CrossRef
  • Two Cases of Ulcerative Colitis-like Gastroduodenitis after Total Proctocolectomy for Intractable Ulcerative Colitis
    Takahiro SHIMOYAMA, Takayuki YAMAMOTO, Yasuhiro INOUE, Satoru UMEGAE
    Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association).2019; 80(5): 904.     CrossRef
  • 11,524 View
  • 177 Download
  • 6 Web of Science
  • 8 Crossref
Close layer
Brief Communication
Colorectal neoplasia
Lack of reliability of self-reports by patients with advanced colorectal polyps
Benjamin Fiedler, Lawrence Fiedler, Michael A. DeDonno, Kosi Anago, Leonie de la Cruz, George R. Luck, Charles H. Hennekens
Intest Res 2019;17(2):278-280.   Published online December 14, 2018
DOI: https://doi.org/10.5217/ir.2018.00144
PDFPubReaderePub

Citations

Citations to this article as recorded by  
  • Underutilization of Aspirin in Patients With Advanced Colorectal Polyps
    Benjamin Fiedler, Lawrence Fiedler, Michael DeDonno, Kosi Anago, Leonie de la Cruz, George R. Luck, Charles H. Hennekens
    The American Journal of Medicine.2019;[Epub]     CrossRef
  • 5,337 View
  • 87 Download
  • 1 Web of Science
  • 1 Crossref
Close layer
Images of the Issue
Endoscopy
Rectal polypoid lesion with a nodular surface
Jae Hyun Kim
Intest Res 2019;17(2):281-282.   Published online February 7, 2019
DOI: https://doi.org/10.5217/ir.2018.00172
PDFPubReaderePub
  • 5,581 View
  • 88 Download
Close layer

Intest Res : Intestinal Research
Close layer
TOP